Figure 1.
Pharmacodynamic markers over time following single doses of ACT‐389949. (A) Arithmetic mean [and 95% confidence interval (CI) for placebo] formyl peptide receptor type 2 (FPR2)/ surface expression on monocytes measured as mean fluorescence intensity (MFI). (B) Arithmetic mean (and 95% CI for placebo) tumour necrosis factor α (TNF‐α) levels in plasma by dose group